Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model

Sara M Atkinson, Anneline Nansen, Pernille A Usher, Bodil C Sondergaard, Charles R Mackay, Birgitte N Friedrichsen, Chih-Chuan Chang, Renhong Tang, Soren Skov, Claus G Haase, Lars Hornum

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such interventions during the early phases of arthritis remain to be clarified. In this study we use the murine delayed-type hypersensitivity arthritis (DTHA) model to study the very early effects of a blocking, non-depleting anti-C5aR mAb on joint inflammation with treatment synchronised with disease onset, an approach not previously described. The DTHA model is a single-paw inflammatory arthritis model characterised by synchronised and rapid disease onset driven by T-cells, immune complexes and neutrophils. We show that a reduction in paw swelling, bone erosion, cartilage destruction, synovitis and new bone formation is apparent as little as 60 h after administration of a single dose of a blocking, non-depleting anti-mouse C5aR mAb. Importantly, infiltration of neutrophils into the joint and synovium is also reduced following a single dose, demonstrating that C5aR signalling during the early stage of arthritis regulates neutrophil infiltration and activation. Furthermore, the number of T-cells in circulation and in the draining popliteal lymph node is also reduced following a single dose of anti-C5aR, suggesting that modulation of the C5a/C5aR axis results in effects on the T cell compartment in inflammatory arthritis. In summary, these data demonstrate that blockade of C5aR leads to rapid and significant effects on arthritic disease development in a DTHA model strengthening the rationale of C5aR-blockade as a treatment strategy for RA, especially during the early stages of arthritis flare.
Original languageEnglish
Pages (from-to)460 - 470
Number of pages11
JournalAutoimmunity
Volume48
Issue number7
DOIs
Publication statusPublished - 2015

Cite this

Atkinson, Sara M ; Nansen, Anneline ; Usher, Pernille A ; Sondergaard, Bodil C ; Mackay, Charles R ; Friedrichsen, Birgitte N ; Chang, Chih-Chuan ; Tang, Renhong ; Skov, Soren ; Haase, Claus G ; Hornum, Lars. / Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model. In: Autoimmunity. 2015 ; Vol. 48, No. 7. pp. 460 - 470.
@article{df77a574a744456cae8e4ecbc6d01f08,
title = "Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model",
abstract = "Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such interventions during the early phases of arthritis remain to be clarified. In this study we use the murine delayed-type hypersensitivity arthritis (DTHA) model to study the very early effects of a blocking, non-depleting anti-C5aR mAb on joint inflammation with treatment synchronised with disease onset, an approach not previously described. The DTHA model is a single-paw inflammatory arthritis model characterised by synchronised and rapid disease onset driven by T-cells, immune complexes and neutrophils. We show that a reduction in paw swelling, bone erosion, cartilage destruction, synovitis and new bone formation is apparent as little as 60 h after administration of a single dose of a blocking, non-depleting anti-mouse C5aR mAb. Importantly, infiltration of neutrophils into the joint and synovium is also reduced following a single dose, demonstrating that C5aR signalling during the early stage of arthritis regulates neutrophil infiltration and activation. Furthermore, the number of T-cells in circulation and in the draining popliteal lymph node is also reduced following a single dose of anti-C5aR, suggesting that modulation of the C5a/C5aR axis results in effects on the T cell compartment in inflammatory arthritis. In summary, these data demonstrate that blockade of C5aR leads to rapid and significant effects on arthritic disease development in a DTHA model strengthening the rationale of C5aR-blockade as a treatment strategy for RA, especially during the early stages of arthritis flare.",
author = "Atkinson, {Sara M} and Anneline Nansen and Usher, {Pernille A} and Sondergaard, {Bodil C} and Mackay, {Charles R} and Friedrichsen, {Birgitte N} and Chih-Chuan Chang and Renhong Tang and Soren Skov and Haase, {Claus G} and Lars Hornum",
year = "2015",
doi = "10.3109/08916934.2015.1031888",
language = "English",
volume = "48",
pages = "460 -- 470",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Taylor & Francis",
number = "7",

}

Atkinson, SM, Nansen, A, Usher, PA, Sondergaard, BC, Mackay, CR, Friedrichsen, BN, Chang, C-C, Tang, R, Skov, S, Haase, CG & Hornum, L 2015, 'Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model', Autoimmunity, vol. 48, no. 7, pp. 460 - 470. https://doi.org/10.3109/08916934.2015.1031888

Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model. / Atkinson, Sara M; Nansen, Anneline; Usher, Pernille A; Sondergaard, Bodil C; Mackay, Charles R; Friedrichsen, Birgitte N; Chang, Chih-Chuan; Tang, Renhong; Skov, Soren; Haase, Claus G; Hornum, Lars.

In: Autoimmunity, Vol. 48, No. 7, 2015, p. 460 - 470.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model

AU - Atkinson, Sara M

AU - Nansen, Anneline

AU - Usher, Pernille A

AU - Sondergaard, Bodil C

AU - Mackay, Charles R

AU - Friedrichsen, Birgitte N

AU - Chang, Chih-Chuan

AU - Tang, Renhong

AU - Skov, Soren

AU - Haase, Claus G

AU - Hornum, Lars

PY - 2015

Y1 - 2015

N2 - Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such interventions during the early phases of arthritis remain to be clarified. In this study we use the murine delayed-type hypersensitivity arthritis (DTHA) model to study the very early effects of a blocking, non-depleting anti-C5aR mAb on joint inflammation with treatment synchronised with disease onset, an approach not previously described. The DTHA model is a single-paw inflammatory arthritis model characterised by synchronised and rapid disease onset driven by T-cells, immune complexes and neutrophils. We show that a reduction in paw swelling, bone erosion, cartilage destruction, synovitis and new bone formation is apparent as little as 60 h after administration of a single dose of a blocking, non-depleting anti-mouse C5aR mAb. Importantly, infiltration of neutrophils into the joint and synovium is also reduced following a single dose, demonstrating that C5aR signalling during the early stage of arthritis regulates neutrophil infiltration and activation. Furthermore, the number of T-cells in circulation and in the draining popliteal lymph node is also reduced following a single dose of anti-C5aR, suggesting that modulation of the C5a/C5aR axis results in effects on the T cell compartment in inflammatory arthritis. In summary, these data demonstrate that blockade of C5aR leads to rapid and significant effects on arthritic disease development in a DTHA model strengthening the rationale of C5aR-blockade as a treatment strategy for RA, especially during the early stages of arthritis flare.

AB - Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such interventions during the early phases of arthritis remain to be clarified. In this study we use the murine delayed-type hypersensitivity arthritis (DTHA) model to study the very early effects of a blocking, non-depleting anti-C5aR mAb on joint inflammation with treatment synchronised with disease onset, an approach not previously described. The DTHA model is a single-paw inflammatory arthritis model characterised by synchronised and rapid disease onset driven by T-cells, immune complexes and neutrophils. We show that a reduction in paw swelling, bone erosion, cartilage destruction, synovitis and new bone formation is apparent as little as 60 h after administration of a single dose of a blocking, non-depleting anti-mouse C5aR mAb. Importantly, infiltration of neutrophils into the joint and synovium is also reduced following a single dose, demonstrating that C5aR signalling during the early stage of arthritis regulates neutrophil infiltration and activation. Furthermore, the number of T-cells in circulation and in the draining popliteal lymph node is also reduced following a single dose of anti-C5aR, suggesting that modulation of the C5a/C5aR axis results in effects on the T cell compartment in inflammatory arthritis. In summary, these data demonstrate that blockade of C5aR leads to rapid and significant effects on arthritic disease development in a DTHA model strengthening the rationale of C5aR-blockade as a treatment strategy for RA, especially during the early stages of arthritis flare.

UR - http://www.tandfonline.com/doi/pdf/10.3109/08916934.2015.1031888

U2 - 10.3109/08916934.2015.1031888

DO - 10.3109/08916934.2015.1031888

M3 - Article

VL - 48

SP - 460

EP - 470

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 7

ER -